Therapeutic use of a selective cAMP phosphodiesterase inhibitor (Rolipram) in Parkinson's disease.
The effects of Rolipram, a new phosphodiesterase inhibitor, were assessed in a double-blind trial versus placebo in 10 patients with Parkinson's disease already under treatment. Contrary to previous findings with specific phosphodiesterase inhibitors, with Rolipram (at the dose of 3 mg per day), no significant deterioration of the therapeutic action of dopamine agonist Lisuride was noted.